drugset / Trial / NCT04077957
Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs
RandomizedParallel-groupOpen-labelTreatment
Summary
This study evaluates clinical responses and cost-effectiveness of using etanercept (ETN) and conventional synthetic Disease modifying anti-rheumatic drugs (csDMARDs) with treat-to-target strategy in ankylosing spondylitis patients. Half of participants will be used treat-to-target strategy with ETN and csDMARDs, while the others will be used conventional therapy scheme with ETN only.
Timeline
- Start
- 2019-10-07
- Primary completion
- 2021-10-31
- Completion
- 2022-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etanercept | Protein / enzyme biologic | 25 mg | — |
| Subject | Etanercept | Protein / enzyme biologic | 50 mg | — |
| Background | Hydroxychloroquine | Small molecule | 0.2 g | — |
| Background | Methotrexate | Small molecule | 10 mg | — |
| Background | Sulfasalazine | Small molecule | 2.25 g | — |